FPL 62064|cas:103141-09-9|西域试剂

FPL 62064,98.46%

产品编号：Bellancom-105024| CAS NO：103141-09-9| 分子式：C₁₆H₁₅N₃O| 分子量：265.31

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-105024	￥1500.00	杭州北京（现货）
Bellancom-105024	￥2500.00	杭州北京（现货）
Bellancom-105024	￥9500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FPL 62064

产品介绍

FPL 62064 是一种有效的 5-脂氧合酶 (5-LOX) 和 COX 双重抑制剂，对 RBL-1 胞质 5-脂氧合酶和前列腺素合成酶 (环氧化酶) 的 IC₅₀ 值分别为 3.5 μM和 3.1 μM。FPL 62064 具有有效的抗炎活性。

生物活性

FPL 62064 is a potent 5-lipoxygenase (5-LOX) and COX dual inhibitor, with IC₅₀ values of 3.5 μM and 3.1 μM for RBL-1 cytosolic 5-lipoxygenase and prostaglandin synthetase (cyclooxygenase), respectively. FPL 62064 has potent anti-inflammatory activity.

体外研究

FPL 62064 inhibits both 5-1ipoxygenase (IC₅₀ of 3.5 μM for RBL-1 cytosolic 5-1ipoxygenase) and prostaglandin synthetase (IC₅₀ of 3.1 μM for seminal vesicle prostaglandin synthetase ) with equal facility in the isolated enzyme screens. However in the intact RBL-I cell prostaglandin synthetase (IC₅₀ of 3.6 μM) is more readily inhibited by FPL 62064 than is 5-1ipoxygenase (IC₅₀ of 31 μM). This difference in sensitivity is not reflected in the mouse macrophage where the IC₅₀s for leukotriene (IC₅₀ of 0.72 μM) and prostaglandin (IC₅₀ of 0.43 μM) production are similar.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

FPL 62064 (5-20 mg/kg; intraperitoneal injection; female LACA mice) treatment inhibits peritoneal inflammation induced by immune-complex.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female LACA mice (20-30 g) injected with immune complex.
Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:	Intraperitoneal injection
Result:	Produced a dose-related inhibition of dye extravasation, leukotriene C₄ (LTC₄) and prostaglandin E₂ (PGE₂) formation.

体内研究

FPL 62064 (5-20 mg/kg; intraperitoneal injection; female LACA mice) treatment inhibits peritoneal inflammation induced by immune-complex.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female LACA mice (20-30 g) injected with immune complex.
Dosage:	5 mg/kg, 10 mg/kg, 20 mg/kg
Administration:	Intraperitoneal injection
Result:	Produced a dose-related inhibition of dye extravasation, leukotriene C₄ (LTC₄) and prostaglandin E₂ (PGE₂) formation.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (942.29 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.7692 mL	18.8459 mL	37.6918 mL
5 mM	0.7538 mL	3.7692 mL	7.5384 mL
10 mM	0.3769 mL	1.8846 mL	3.7692 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.67 mg/mL (6.29 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (6.29 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.67 mg/mL (6.29 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (6.29 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。